gp120-directed antibody-dependent cellular cytotoxicity as a major determinant of the rate of decline in CD4 percentage in HIV-1 disease

AIDS

Volumn 11, Issue 15, 1997, Pages 1807-1814

  Skowron, Gail ^a,d   Cole, Bernard F ^b   Zheng, Delian ^a   Accetta, Grace ^a   Yen Lieberman, Belinda ^c  

^a ROGER WILLIAMS MEDICAL CENTER   (United States)

^b BROWN UNIVERSITY   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d BROWN UNIVERSITY   (United States)

Author keywords

Antibody dependent cellular cytotoxicity; CD4 antibodies; Cellular immunity; Envelope proteins; Natural killer cells

Indexed keywords

CD4 ANTIGEN; GLYCOPROTEIN GP 120; VIRUS RNA;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; NATURAL KILLER CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

EID: 0030727951     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199715000-00004     Document Type: Article

References (53)

1. Centers for Disease Control: Pneumocystis pneumonia - Los Angeles. MMWR 1981, 30:250-252.
2. Centers for Disease Control: Kaposi's sarcoma and Pneumocystis pneumonia among homosexual men - New York City and California. MMWR 1981, 30:305-308.
3. Pantaleo G, Graziosi C, Fauci AS: The immunopathogenesis of human immunodeficiency virus infection. N Engl J Med 1993, 328:327-335.
4. Garry RF: Potential mechanisms for the cytopathic properties of HIV. AIDS 1989, 3:683-694.
5. Sodroski J, Goh WC, Rosen C, Campbell K, Haseltine WA: Role of the HTLV-III/LAV envelope in syncytium formation and cytopathicity. Nature 1986, 322:470-474.
6. Lifson JD, Reyes GR, McGrath MS, Stein BS, Engleman EG: AIDS retrovirus induced cytopathology: giant cell formation and involvement of CD4 antigen. Science 1986, 232:1123-1127.
7. Imberti L, Sottini A, Bettinardi A, Puoti M, Primi D: Selective depletion in HIV infection of T cells that bear specific T cell receptor Vβ sequences. Science 1991, 254:860-862.
8. Pantaleo G, Rebai N, Graziosi C, Lane HC, Sekaly RP, Fauci AS: Perturbation of the T cell receptor Vβ repertoire in peripheral blood T cells of HIV infected individuals [abstract]. Clin Res 1992, 40 (suppl 2A):253A.
9. Terai C, Kornbluth RS, Pauza CD, Richman DD, Carson DA: Apoptosis as a mechanism of cell death in cultured T lymphoblasts acutely infected with HIV-1. J Clin Invest 1991, 87:1710-1711.
10. Laurent-Crawford AG, Krust B, Muller S, et al.: The cytopathic effect of HIV is associated with apoptosis. Virology 1991, 185:829-839.
11. Groux H, Torpier G, Montë D, Mouton Y, Capron A, Ameisen JC: Activation-induced death by apoptosis in CD4+ T cells from human immunodeficiency virus-infected asymptomatic individuals. J Exp Med 1992, 175:331-340.
12. Banda NK, Bernier J, Kurahara DK, et al.: Crosslinking CD4 by human immunodeficiency virus gp120 primes T cells for activation-induced apoptosis. J Exp Med 1992, 176:1099-1106.
13. Zinkernagel KM, Hengartner H: T-cell-mediated immunopathology versus direct cytolysis by virus: implications for HIV and AIDS. Immunol Today 1994, 15:262-268.
14. Zarling JM, Ledbetter JA, Sias J, et al.: HIV-infected humans, but not chimpanzees, have circulating cytotoxic T lymphocytes that lyse uninfected CD4+ cells. J Immunol 1990, 144:2992-2998.
15. B glycoprotein (gp120) bound to CD4 determinants on normal lymphocytes and expressed by infected cells serves as target for immune attack. Proc Natl Acad Sci USA 1987, 84:4601-4605.
16. Weinhold KJ, Lyerly HK, Stanley SD, Austin AA, Matthews TJ, Bolognesi DP: HIV-1 gp120-mediated immune suppression and lymphocyte destruction in the absence of viral infection. J Immunol 1989, 142:3091-3097.
17. Weinhold KJ, Lyerly HK, Matthews TJ, et al.: Cellular anti-gp120 cytolytic reactivities in HIV-1 seropositive individuals. Lancet 1988, i:902-905.
18. Tyler DS, Nastala CL, Stanley SD, et al.: gp120 specific cellular cytotoxicity in HIV-1 seropositive individuals: evidence for circulating CD16+ effector cells armed in vivo with cytophilic antibody. J Immunol 1989, 142:1177-1182.
19. Cao Y, Qin L, Zhang L, Safrit J, Ho DD: Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Engl J Med 1995, 322:201-208.
20. Pantaleo G, Menzo S, Vaccarezza M, et al.: Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N Engl J Med 1995, 322:209-216.
21. Rump J-A, Peter H-H, Schneider J, Haller O, Meyerhans A: Long-term survivors with continuously high levels of HIV type 1. AIDS Res Hum Retroviruses 1996, 12:757-758.
22. Candotti D, Joberty C, Clauvel JP, et al.: Virologic analysis of HIV-1-infected long term asymptomatic subjects. Fourth Conference on Retroviruses and Opportunistic Infections. Washington, DC, January 1997 [abstract 473].
23. Tyler DS, Stanley SD, Nastala CA, et al.: Alterations in antibody-dependent cellular cytotoxicity during the course of HIV-1 infection: humoral and cellular defects. J Immunol 1990, 144:3375-3384.
24. Ahmad A, Menezes J: Positive correlation between the natural killer and gp120/41-specific antibody-dependent cellular cytotoxic effector functions in HIV-infected individuals. J Acquir Immune Defic Syndr 1995, 10:115-119.
25. Trinchieri G: Biology of natural killer cells. Adv Immunol 1989, 47:187-376.
26. Unkeless JC, Scigliano E, Freedman VH: Structure and function of human and murine receptors for IgG. Ann Rev Immunol 1988, 6:251-281.
27. Margolick JB, Munoz A, Donnenberg AD, et al.: Failure of T-cell homeostasis preceding AIDS in HIV-1 infection. Nature Med 1995, 1:674-680.
28. 6/1. AIDS 1995, 9:145-152.
29. Wei X, Ghosh SK, Taylor ME, et al.: Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995, 373:117-122.
30. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995, 373:123-126.
31. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD: HIV-1 dynamics in vivo: virion clearance rate, infected cell lifespan, and viral generation time. Science 1996, 271:1582-1586.
32. Coffin JM: HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995, 267:483-489.
33. Dimitrov DS, Martin MA: HIV results in the frame, CD4+ cell turnover [letter; comment]. Nature 1995, 375:194-195.
34. Ascher MS, Sheppard HW, Anderson RW, Krowka JL, Bremermann HJ: HIV results in the frame, Paradox remains [letter; comment]. Nature 1995, 375:196.
35. Finkel JH, Tudor-Williams G, Banda NK, et al.: Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV- and SIV-infected lymph nodes. Nature Med 1995, 1:129-134.
36. Stacey NH, Bishop CJ, Halliday JW, et al.: Apoptosis as the mode of cell death in antibody-dependent lymphocytotoxicity. J Cell Sci 1985, 74:169-179.
37. Trapani JA, Smyth MJ: Killing by cytotoxic T cells and natural killer cells: multiple granule serine proteases as initiators of DNA fragmentation. Immunol Cell Biol 1993, 71:201-208.
38. Berke G: Unlocking the secrets of CTL and NK cells. Immunol Today 1995, 16:343-346.
39. Oh Sk, Cruikshank WW, Raina J: Identification of HIV-1 envelope glycoprotein in the serum of AIDS and ARC patients. J Acquir Immune Defic Syndr 1992, 5:251-256.
40. Gilbert M, Kirihara J, Mills J: Enzyme-linked immunoassay for human immunodeficiency virus type 1 envelope glycoprotein 120. J Clin Microb 1991, 29:142-147.
41. Daniel V, Susal C, Prodeus AP, et al.: CD4+ lymphocyte depletion in HIV-infected patients is associated with gp120-immunoglobulin-complement attachment to CD4+ cells. Vox Sang 1993, 64:31-36.
42. Sunila I, Vaccarezza M, Panteleo G, Lauci AS, Orenstein JM: gp120 is present on the plasma membrane of apoptotic CD4 cells prepared from lymph nodes of HIV-1-infected individuals: an immunoelectron microscopic study. AIDS 1997, 11:27-32.
43. Rook AH, Lane HC, Folks I, McCoy S, Alter H, Lauci AS: Sera from HTLV-III/LAV antibody-positive individuals mediate antibody-dependent cellular cytotoxicity against HTLV-III/LAV-infected T cells. J Immunol 1987, 138:1064-1067.
44. Brenner BG, Dascal A, Margolese RG, Wainberg MA: Natural killer function in patients with acquired immunodeficiency syndrome and related diseases. J Leukoc Biol 1989, 46:75-83.
45. Sawyer LA, Katzenstein DA, Hendry RM, et al.: Possible beneficial effects of neutralizing antibodies and antibody-dependent, cell-mediated cytotoxicity in human immunodeficiency virus infection. AIDS Res Hum Retroviruses 1990, 6:341-356.
46. Ahmad A, Morisset R, Thomas R, Menezes J: Evidence for a defect of antibody-dependent cellular cytotoxic (ADCC) effector function and anti-HIV gp120/41-specific ADCC-mediating antibody titres in HIV-infected individuals. J Acquir Immune Defic Syndr 1994, 7:428-437.
47. dimCD56- cells with low lytic activity. J Acquir Immune Defic Syndr 1995, 10:331-340.
48. Connor RI, Mohri H, Cao Y, Ho DD: Increased viral burden and cytopathicity correlate temporally with CD4+ T-lymphocyte decline and clinical progression in human immunodeficiency virus type 1-infected individuals. J Virol 1993, 67:1772-1777.
49. Terrari G, Place CA, Ahearne PM, et al.: Comparison of anti-HIV-1 ADCC reactivities in infected humans and chimpanzees. J Acquir Immune Defic Syndr 1994, 7:325-331.
50. Nara P, Hatch W, Kessler J, Kelliher J, Carter S: The biology of human immunodeficiency virus-1 IIIB infection in the chimpanzee: in vivo and in vitro correlations. J Med Primatol 1989, 18:343-355.
51. Baum IL, Cassutt KJ, Knigge K, et al.: HIV-1 gp120-specific antibody dependent cell-mediated cytotoxicity correlates with rate of disease progression. J Immunol 1996, 157:2168-2173.
52. O'Brien WA, Hartigan PM, Martin D, et al.: Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. N Engl J Med 1996, 334:426-431.
53. Yerly S, Kaiser L, Mermillod B, Baumberger C, Hirschel B, Perrin I : Response of HIV RNA to didanosine as a predictive marker of survival. AIDS 1995, 9:159-163.